Why is lung adenocarcinoma not responding to targeted therapy?

Hello,

Welcome to icliniq.com.

I have read your query and understand your concern.

In lung adenocarcinoma, some tumors develop specific genetic mutations that drive the cancer’s growth. One of the most common of these is the EGFR (epidermal growth factor receptor) mutation.

When this mutation is present, the cancer cells depend heavily on that pathway to keep growing.

Targeted therapy medicines are designed to block this exact pathway. Because the drug directly interferes with the signal that is helping the cancer grow, the tumor often shrinks quickly once treatment begins.

This is why many patients with EGFR-positive lung cancer show a noticeable response within the first few months of therapy, just like your father experienced.

Yes, when a lung cancer has a known driver mutation such as EGFR, targeted therapy usually works better than standard chemotherapy. Chemotherapy affects all fast-growing cells in the body and works in a more general way.

Targeted therapy, on the other hand, focuses on the specific abnormal mechanism inside the cancer cell. Because of this, response rates are higher, and patients often feel symptom relief earlier.

In clinical practice, we frequently see significant tumor shrinkage in patients who start the correct targeted medicine after mutation testing. The response your father had is considered a very positive sign because it shows that the treatment is effectively controlling the cancer at this stage.

In my own clinical experience, I have seen several patients with EGFR-positive lung adenocarcinoma remain stable for quite a long period while continuing their targeted tablets and regular follow-up scans.

However, it is also true that over time, some cancers can slowly develop resistance to the medication. This does not mean the treatment has failed immediately, but the cancer cells may eventually find another pathway to grow.

If that happens later, doctors usually repeat molecular testing or perform a liquid biopsy to look for new mutations and then adjust the treatment accordingly.

Many newer targeted medicines are available today for such situations. So the strong response your father had mainly indicates that the cancer is sensitive to the targeted therapy he is receiving, which is encouraging for disease control and symptom improvement.

I hope I have addressed all of your queries and concerns.

Do follow up for further queries.

Best wishes.